ResearcherKingston University LondonActive in the last 2 years
Helmout Modjtahedi
Matched on ORCID iD 0000-0002-5509-7415; OpenAlex author ID A5010891764. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 6)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 5
2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 7
- [Corrigendum] Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER‑inhibitors is accompanied by increased sensitivity to STAT3 … Last author DOI 10.3892/ijo.2026.5948↗
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. First author DOI 10.3390/cancers13081781↗
- Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer. Last author DOI 10.1038/s41598-019-57287-w↗
- Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the id… Last author DOI 10.3892/or.2020.7822↗
- Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. Last author DOI 10.18632/oncotarget.25017↗
- Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. Last author DOI 10.3892/ijo.2016.3320↗
- Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human panc… Last author DOI 10.1186/1471-2407-13-41↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Angus George Dalgleish · 6 shared papers, 2013–2026 · strength 0.83
- Paper [Corrigendum] Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER‑inhibitors is accomp… DOI 10.3892/ijo.2026.5948↗
- Paper Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human panc… DOI 10.1038/s41598-019-57287-w↗
- Paper Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of… DOI 10.3892/or.2020.7822↗
- Nikolaos Ioannou · 4 shared papers, 2013–2026 · strength 0.60
- Paper [Corrigendum] Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER‑inhibitors is accomp… DOI 10.3892/ijo.2026.5948↗
- Paper Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of… DOI 10.3892/or.2020.7822↗
- Paper Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by incre… DOI 10.3892/ijo.2016.3320↗
- Gustavo A. Arias-Pinilla · 3 shared papers, 2018–2021 · strength 0.51
- Paper Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. DOI 10.3390/cancers13081781↗
- Paper Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human panc… DOI 10.1038/s41598-019-57287-w↗
- Paper Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. DOI 10.18632/oncotarget.25017↗
- Satvinder Mudan · 3 shared papers, 2018–2020 · strength 0.36
- Paper Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human panc… DOI 10.1038/s41598-019-57287-w↗
- Paper Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of… DOI 10.3892/or.2020.7822↗
- Paper Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. DOI 10.18632/oncotarget.25017↗
- Tanzeel Khan · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.